SK-BR-3 Xenograft Model Service for Breast Cancer

The SK-BR-3 xenograft model provides a highly validated, clinically relevant in vivo translational platform specifically optimized for evaluating candidate therapies, antibody-drug conjugates, and novel combination strategies targeting HER2-overexpressing breast cancer. Alfa Cytology delivers a comprehensive, end-to-end SK-BR-3 xenograft model service, integrating fully authenticated cellular assets with standardized procedural protocols to accelerate preclinical oncology drug discovery timelines.

Overview of SK-BR-3 Xenograft Model for Breast Cancer

The SK-BR-3 cell line is a widely utilized and exceptionally well-characterized human mammary carcinoma model in preclinical oncology, serving as a classic representative of the HER2-positive (HER2-enriched) molecular subtype of breast cancer. Originally isolated from the pleural effusion of a 43-year-old Caucasian female patient with metastatic malignant adenocarcinoma, this model is phenotypically defined by a massive amplification of the ERBB2 (HER2) gene alongside the absolute absence of ER and PR expression. Unlike triple-negative lines, SK-BR-3 preserves distinct epithelial features and exhibits a prominent genomic hallmark of HER2 overexpression, making it a foundational test matrix for validating novel anti-HER2 monoclonal antibodies, small-molecule tyrosine kinase inhibitors (TKIs), and next-generation HER2-targeted ADCs.

When established in vivo as a xenograft in immunocompromised mice, SK-BR-3 cells form solid, moderately differentiated tumors that closely mirror the aggressive clinical progression, histopathological traits, and therapeutic vulnerability profiles observed in HER2-positive breast cancer patients.

Fig 1. Antitumor activity of humH2Mab-250 against CHO/HER2, BT-474, and SK-BR-3 xenografts. (Kaneko MK, et al., 2025)

Cell Line Information: SK-BR-3

The SK-BR-3 cell line maintains a distinct epithelial morphology in vitro and reliably preserves its signature HER2 amplification and ER-/PR- status upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the SK-BR-3 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC for HER2 expression and PK/PD profiling. Leveraging our expertise in HER2-positive breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of SK-BR-3 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the SK-BR-3 xenograft model:

• Cell Culture & Quality Control: SK-BR-3 cells are cultured in cell bank-certified growth medium under optimized conditions. Quality control verification involves mandatory STR profiling and mycoplasma clearance checks to guarantee phenotypic identity and purity before inoculation.
• Host Selection & Acclimatization: Standardized immunocompromised mice (e.g., BALB/c Nude, NOD/SCID) are selected based on specific study requirements and acclimated to controlled facility parameters to ensure baseline physiological stability.
• Precision Inoculation: A calibrated suspension of high-viability SK-BR-3 cells is prepared and blended with a verified biological matrix carrier to optimize spatial distribution and support initial engraftment. The mixture is precisely injected in vivo via subcutaneous or orthotopic routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers under continuous health monitoring. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 2. SK-BR-3 Xenograft Model Construction Workflow

Case Study - SK-BR-3 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the SK-BR-3 xenograft model was successfully utilized to evaluate the efficacy of a novel next-generation ADC targeting overexpressed HER2 receptors. Under optimized modeling conditions and standardized inoculation protocols, our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms, allowing for an unobstructed and definitive assessment of therapeutic efficacy.

Our Advantages

Choosing the right partner for your HER2-amplified breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified human tumor cell lines with stable, traceable genetic hallmarks and confirmed high HER2 expression.
• Technical Consistency: Optimized inoculation protocols utilizing customized matrix support to ensure uniform tumor growth and minimize variance.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics, target receptor expression analysis, and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research and animal welfare standards.

Contact Us

Are you looking to advance your therapeutic pipeline against aggressive, HER2-amplified breast cancer using the robust SK-BR-3 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.